WOMEN 'S HEALTH AND MENOPAUSE : - National Heart, Lung ...

TABLE 11–3 (continued)
Case-Control Studies (continued)
Reference
Harlow et al., 97 1988,
U.S.A.
Kaufman et al., 98 1989,
U.S.A.
Booth et al., 99 1989, UK
Polychronopoulou et al., 100
1993, Greece
Parazzini et al., 101 1994,
Italy
Purdie et al., 102 1995,
Australia
Risch et al., 103 1996,
Ontario, Canada
Hempling et al., 104 1997,
U.S.A.
Study Design
Hospital-based
Hospital-based
Hospital-based
Hospital-based
Hospital-based
Population-based
Population-based
Hospital-based
No. of Cases
(Age Group)
116
(20–59)
377
(18–69)
158
(< 65)
152
(30–64)
953
(23–74)
824
(18–79)
367
491
Relative Risks
for Ever HRT Use
0.9
1.2
1.5
1.4
1.6
1.0
1.3
0.9
Observations
Borderline ovarian neoplasms.
No consistent
duration-risk relationship.
Unopposed estrogen
only. No association
with combined treatment
(OR 0.7) or with specific
histotypes. Some duration-risk
relationship.
Nonsignificant
(95% CI 0.9–2.6).
No association with
specific histotypes.
Nonsignificant
(95% CI 0.4–4.9).
Adjusted for major
covariates, including
oral contraceptive use.
95% CI 1.2–2.3.
Modest duration-risk
relationship.
Multivariate OR, 95%
CI 0.8–1.3.
Multivariate OR 2.0
for serous and 2.8 for
mucinous for ≥ 4 years
of use. No association
with mucinous tumours.
Other cancers as controls.
No duration-risk
relationship.
233